|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **mAb**  | **modification** | **% modified (stressed)** | **motif**  | **location**  |
| mAb14 | suc | 2.9 | ?# | LC CDR 1 |
| mAb2 | iD | 2.8 | DS | LC CDR 2 |
| Trastuzumab | suc | 2.8 | NG | HC CDR 2 |
| Trastuzumab | suc | 2.3 | DG | HC CDR 3 |
| mAb16 | suc | 2.2 | NT | HC CDR 2 |
| mAb33 | suc | 2.0 | DD or DA | HC CDR 3 |
| Trastuzumab | dea  | 2.0 | NG | HC CDR 2 |
| mAb12 | suc | 1.9 | DG | HC CDR 2 |
| mAb11 | suc | 1.8 | DG | HC CDR 2 |
| mAb16 | suc | 1.8 | DD | HC CDR 2 |
| Natalizumab | dea  | 1.4 | NG | HC CDR 2 |
| mAb2 | suc | 1.3 | NN | LC CDR 1 |
| mAb1 | iD+suc | 1.0 | DS | HC CDR 2 |
| mAb2 | suc | 1.0 | DS | LC CDR 3 |

#proof of modification site impossible with available methods